The new issue prior to listing on AktieTorget heavily oversubscribed
The subscription period of Oncology Venture Sweden AB’s new issue at the AktieTorget ended on the 24th of June 2015. The new issue was subscribed for approximately 77,8 MSEK including garantors which corresponds to a subscription rate of about 370 percent. 2.840.000 new shares were issued. Oncology Venture will accordingly be provided with 19,7 million SEK after issue costs (which is approximately 1,3 million SEK). And with approximately 1,340 new shareholders. Contract notes are expected to be sent to the subscribers today on the 29th of June 2015.
CEO, MD, PhD, Professor of Clinical Oncology Peter Buhl Jensen comments
– We are very proud of the positive result and I want to thank all of the 1,340 new shareholders. Through the new capital Oncology Venture is given the right conditions to run the company to fulfill our ambitious aims.
Listing at the AktieTorget
First day of trading is planned for the 22 of July 2015. The trading code will be OV and the ISIN-code is SE0007157409.
Number of shares and share capital
After the new emission has been registered at the Bolagsverket the total number of shares in Oncology Venture will increase to 7.233.186 shares and the share capital will increase to 1.012.646,04 SEK (nominal value of 0,14 SEK).
Sedermera Fondskommission has acted as Oncology Ventures financial advisor in relation to the new issue prior to listing at the AktieTorget.
For questions related to the new issue:
Telephone: 0431-47 17 00
For further Information about Oncology Venture:
Peter Buhl Jensen, CEO
Telephone: +45 21 60 89 22
About Oncology Venture
Oncology Venture Sweden AB runs anti-cancer drug development through the wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™– to significantly increase the likelihood of success in clinical studies. The Company aims to rescue anti-cancer drugs which have previously stopped in clinical development. DRP™ has demonstrated its ability to predict clinical results of anti-cancer treatment in patients in 26 out of 32 clinical studies with statistical significance.
The Company operates with a model that changes the odds in conventional anti-cancer drug development. Instead of treating all patients with the same type of cancer the patients will be screened. Only those patients with the highest likelihood of response to the treatment will hereafter be treated. Through more well defined patient population risks and costs are reduced and development will be more effective.